Publications

Image001

The Impact of Health Technology Assessment on Drug Development

3 January 2009

Health technology assessment (HTA) has become a critical basis for pricing and reimbursement decision-making worldwide. In some countries, extensive requirements for data are set out in…

320 - assessment and appraisal

Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience

1 February 2009

Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines…

318 - CompendiumOfHealth_2009

Compendium of Health Statistics

1 January 2009

The annual OHE Compendium of Health Statistics is the one-stop statistical information source on population and health trends in the UK, and the changing finances and…

QALYs versus Experience: A Perspective from Experimental Economics

1 August 2008

OHE’s 14th Annual Lecture was delivered by Professor Daniel Kahneman, winner of the 2002 Nobel Prize in Economic Sciences for his pioneering work integrating insights from…

NHS Outcomes, Performance and Productivity

3 March 2008

OHE established a Commission on NHS Outcomes, Performance and Productivity. It’s overall conclusion was that the collection and use of outcomes measures in the NHS is both practical and essential.

317 - MedicalResearchWhat_Nov2008_BIG

Medical Research: What’s It Worth?

1 November 2008

Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study.…

316 - NewGuidelines_Nov2008_BIG

New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?

1 November 2008

Australia was the first, in 1993, to make economic evaluation an important component of its decisions about reimbursement of drugs.  Since then, several jurisdictions have followed…

Cracks through the ice on a melting glacier in Alaska

The Market for Biosimilars: Evolution and Policy Options

1 November 2008

The authors point out that biopharmaceuticals are more complex agents than conventional chemical entities and therefore are more difficult to replicate after  patent expiry. Off-patent versions…

313 - HealthCareServices_Sept2008_BIG

Health Care Services and the Single European Market

1 September 2008

In 2008, the European Commission published a proposal for a Directive on the application of patients’ rights in cross-border health care.  This followed two 1998 landmark…